Plasma Exchange (Plasmapheresis)
A fast-acting procedure that physically removes harmful antibodies from the blood
Route
Intravenous procedure (central venous catheter)
Frequency
5–6 sessions over 10–14 days (per acute course)
Setting
Hospital or specialized apheresis center
FDA Status
Not FDA-approved for CIDP specifically; Level A evidence in EAN/PNS 2021 guideline
Educational use only. This page explains how Plasma Exchange works based on clinical guidelines and trial data. It cannot replace your neurologist. All treatment decisions must be made with your medical team.
How Plasma Exchange Works
Plasma exchange (also called plasmapheresis or therapeutic plasma exchange / TPE) physically removes the blood plasma — the liquid component that contains the harmful antibodies causing nerve damage in CIDP — and replaces it with albumin solution. Unlike IVIG and Vyvgart Hytrulo, which work immunologically, plasma exchange works mechanically: it directly clears pathogenic antibodies from the circulation.
- •Blood is drawn through a central venous catheter and passed through an apheresis machine
- •The machine uses centrifugation or membrane filtration to separate plasma from blood cells (red cells, white cells, platelets)
- •The removed plasma — which contains IgG antibodies including the pathogenic anti-myelin antibodies — is discarded
- •The blood cells are returned to the patient along with 5% albumin replacement solution (occasionally fresh frozen plasma)
- •Each session removes approximately 1.0–1.5 plasma volumes (3–4 liters in an average adult)
- •A typical course of 5–6 sessions over 10–14 days reduces circulating IgG by approximately 70–80%
- •Because it does not address the underlying immune dysregulation, the effect is temporary — pathogenic antibodies rebound as the immune system continues producing them
Clinical Evidence
Plasma exchange carries Level A evidence in the 2021 EAN/PNS CIDP guideline — equal to IVIG and corticosteroids — making it a fully guideline-endorsed first-line option for acute CIDP treatment. Its primary advantage over IVIG is speed of onset.
| Metric | Value | Source |
|---|---|---|
| Evidence level | Level A | EAN/PNS 2021 guideline |
| Time to response | 1–4 days after first session | EAN/PNS 2021 |
| IgG reduction per course | ~70–80% | Apheresis literature |
| Sessions per course | 5–6 over 10–14 days | Standard protocol |
| Duration of effect | 4–8 weeks (variable) | EAN/PNS 2021 |
| Equivalence to IVIG | Equivalent in head-to-head trials | Dyck et al., Ann Neurol 1994 |
Plasma exchange is most valuable in specific clinical scenarios: when a very rapid response is needed (e.g., a patient rapidly losing function), when IVIG is contraindicated (IgA deficiency), when IVIG has failed to produce adequate response, or as a bridge before a scheduled surgical procedure.
Because the effects are temporary (4–8 weeks), plasma exchange is rarely used as long-term maintenance therapy. Most patients who respond are transitioned to IVIG or SCIg for ongoing disease control.
Side Effects
Common
- •Hypotension (low blood pressure) during the procedure — common, usually managed with IV fluids
- •Tingling or cramping from citrate anticoagulant (citrate binds calcium) — treated with calcium infusion
- •Nausea during the procedure
- •Fatigue for 1–2 days after each session
- •Mild anemia from the procedure itself
Serious (less common)
- •Central line complications: infection (bacteremia), thrombosis, pneumothorax from catheter placement
- •Temporary bleeding risk: plasma exchange removes clotting factors along with antibodies; fibrinogen and other factors typically normalize within 24–48 hours
- •Electrolyte imbalances (calcium, potassium) — monitored during procedure
- •Allergic reactions to replacement albumin (uncommon)
- •Air embolism (rare, procedural complication)
The procedural risks of central venous catheter placement are the most significant safety concern, particularly for patients who need repeated courses. Experienced apheresis centers minimize these risks. Patients on blood thinners or with coagulation disorders require careful management around each session.
Pros & Cons
Advantages
- ✓Fastest onset of any CIDP treatment — response often within 1–4 days
- ✓Directly removes pathogenic antibodies (not immunological modulation)
- ✓Level A evidence — fully guideline-endorsed
- ✓Works when IVIG has failed
- ✓Safe for IgA-deficient patients (IVIG is contraindicated in IgA deficiency)
- ✓Useful as a bridge when rapid stabilization is needed
Drawbacks
- –Requires hospitalization or specialized apheresis center
- –Central line placement carries procedural risks (infection, bleeding)
- –Temporary effect — pathogenic antibodies rebound within 4–8 weeks
- –Impractical for long-term maintenance
- –Each session takes 2–4 hours
- –Removes clotting factors (temporary bleeding risk)
- –Not widely available outside major medical centers
Insurance & Access
- →Generally covered when IVIG is contraindicated (IgA deficiency) or has failed — document both in the prior authorization request
- →Coverage often requires inpatient or outpatient hospital setting with an experienced apheresis team
- →Less commonly authorized as first-line therapy unless there is a specific contraindication to IVIG
- →Medicare covers therapeutic plasma exchange under Part B with appropriate diagnosis coding
- →If denied, cite the EAN/PNS 2021 Level A evidence and clinical necessity for rapid response or IVIG failure
Have a question about Plasma Exchange?
Ask the AI assistant for more detail — dosing questions, wearing-off, insurance appeals, how Plasma Exchange compares to other options, and more.
Ask the AI →Other CIDP Treatments
IVIG
The most widely used first-line treatment for CIDP, with Level A evidence
Vyvgart Hytrulo
First FDA-approved FcRn inhibitor for CIDP — a 30-second weekly injection at home
SCIg
Weekly home injections that eliminate infusion center visits and the wearing-off effect
Corticosteroids
Oral or IV steroids that broadly suppress immune activity — effective but with long-term trade-offs
Sources
- van den Bergh PYK, et al. EAN/PNS Guideline on CIDP. Eur J Neurol. 2021;28(11):3556–3583.
- Dyck PJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314(8):461–465.
- Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349(9047):225–230.